Introduction of New Drug Discovery Modalities and Regenerative Medicine Development
First written in FY2022. 7 of 9 entries say "Advanced", first in FY2023. Latest entry: 2026-08-03.
1 other company's latest entry also says "Advanced".
- 2026-08-03AdvancedEarnings
「In nucleic acid medicines, we are concentrating on drug discovery research for siRNA medicines with a view to securing a competitive advantage, while actively recruiting highly specialized personnel and acquiring drug discovery technologies. In cell therapies, we are partnering with companies that possess expertise and technologies in regenerative medicine and advancing the development of treatments using SHED, stem cells from human exfoliated deciduous teeth, and REC, highly purified mesenchymal stem cells.」
Describes specific progress in new drug discovery modalities, including a focus on siRNA medicines, the acquisition of specialized personnel and technologies, and the development of cell therapies. - FY2026AdvancedAnnual report
「In nucleic acid medicines, we are concentrating on drug discovery research for siRNA medicines with a view to securing a competitive advantage, while actively recruiting highly specialized personnel and acquiring drug discovery technologies. In cell therapies, we are partnering with companies that possess expertise and technologies in regenerative medicine and advancing the development of treatments using SHED, stem cells from human exfoliated deciduous teeth, and REC, highly purified mesenchymal stem cells.」
Among the new modalities, the company is prioritising siRNA medicines and cell therapies, while securing specialised personnel, acquiring technologies and pursuing corporate partnerships. - FY2025AdvancedAnnual report
「In the biomaterials business, which we position as one of the next-generation pillars, dMD-001, a cartilage repair material, is undergoing an application for marketing approval. dMD-002, a treatment material for cavernous nerve injury, began a confirmatory clinical trial in December 2024. ReFeel, a nerve regeneration guidance material, obtained US 510(k) clearance in June 2024 and began sales to collect clinical data.」
As specific developments in new drug discovery and regenerative medicine modalities, the company reports the marketing approval application for dMD-001, the start of a confirmatory clinical trial for dMD-002, and the acquisition of US 510(k) clearance and launch of sales for ReFeel. - FY2024AdvancedAnnual report
「In the field of regenerative medicine products, we advanced projects involving 3 cell types: human dental pulp stem cells (SHED), high-purity mesenchymal stem cells (REC), and umbilical cord-derived cells (HLC-001).」
The company states that it advanced 3 cell projects involving SHED, REC and HLC-001 in regenerative medicine products. - FY2024-Q1AdvancedAnnual report
「Following the additional acquisition of shares in PuREC Co., Ltd., the company included PuREC Co., Ltd. within the scope of application of the equity method.」
The company reports specific progress involving PuREC株式会社, its partner in the regenerative medicine products and mesenchymal stem cell fields, which became an equity-method associate through an additional share acquisition. - FY2023AdvancedAnnual report
「Regenerative medicine products are one of our priority areas, and we are prioritising projects involving mesenchymal stem cells. In January 2023, we entered into a business alliance agreement with PuREC株式会社 covering the development of manufacturing processes for high-purity mesenchymal stem cell REC and related activities.」
The company has prioritised regenerative medicine products among its new drug discovery modalities and has progressed to a specific business alliance involving mesenchymal stem cell REC. - FY2022First statedAnnual report
「We will incorporate new drug discovery modalities, including cells, nucleic acids and genes. In particular, we will prioritise development in the field of regenerative medicine products.」
The 22-24 Medium-Term Management Plan explicitly states for the first time that, in addition to conventional small-molecule and antibody medicines, the company will incorporate cells, nucleic acids and genes and prioritise the development of regenerative medicine products.